Search
Carmustine
go.drugbank.com/drugs/DB00262ApprovedInvestigational(From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). … It is used in the treatment of brain tumors and various other malignant neoplasms.
Products: Bimustin 100 mg İnfüzyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 adet toz içeren flakon ve 1 adet çözücü flakon, BİCNU 100 MG ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON VE ÇÖZÜCÜSÜ, 1 ADET TOZ FLAKON, 1 ADET ÇÖZÜCÜRetifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigationalRetifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed … By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells.
Categories: Programmed Death Receptor-1 Blocking AntibodyTirofiban
go.drugbank.com/drugs/DB00775ApprovedInvestigationalIt is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. … Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery.
Emicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. … The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents.
Miglitol
go.drugbank.com/drugs/DB00491ApprovedMiglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet. … monosaccharides which can be absorbed by the body.
Guselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalIL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357]. … Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Interferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalInterferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles i...
Mixtures: Rebetron Ready To Use Solution (albumin(human)free) (6000000 Iu/ml and 200mg Capsules)Dienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalDienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. … It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself.
Categories: Sex Hormones and Modulators of the Genital SystemProducts: DIENOGEST E ETINILESTRADIOLO DOCSalsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalThe usefulness of salicylic acid, the active in vivo product of salsalate, in the treatment of arthritic disorders has been established. … A significant portion of the parent compound is absorbed unchanged and undergoes rapid esterase hydrolysis in the body. The parent compound has an elimination half-life of about 1 hour.
Relatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic